All In Biotech

Drug Trial Radar · NCT01393912

PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma

Platelet Derived Growth Factor Receptor (PDGFR) Inhibitor Crenolanib in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma Including Diffuse Intrinsic Pontine Glioma

Last checked: Nov 19, 2026Latest source record: Apr 26, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

55

Actual

Start

Jul 2011

Primary completion

Sep 2014

Study completion Oct 2016

Sponsor

Lead sponsor
St. Jude Children's Research HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Arog Pharmaceuticals, Inc.; The V Foundation for Cancer Research
First posted
Jul 13, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 months, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I clinical trial evaluating crenolanib (CP-868,596), an inhibitor of Platelet Derived Growth Factor Receptor (PDGFR)-kinase in children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) (Stratum A) or in recurrent, progressive or refractory High Grade Glioma (HGG) including DIPG (Stratum B). This study drug targets the most commonly amplified region of genome found in DIPG and pediatric high grade glioma (HGG) which encodes for the PDGF receptor kinase. An oral investigational agent crenolanib will be administered daily during and after local radiation therapy (RT) in Diffuse Intrinsic Pontine Glioma DIPG (Stratum A), or daily for children with recurrent/refractory HGG (Stratum B).

Conditions

  • Diffuse Intrinsic Pontine Glioma
  • Progressive or Refractory High-Grade Glioma

Interventions

  • CrenolanibDrug

    Crenolanib orally administered as whole or crushed tablets once per day with concurrent Radiation Therapy. Crenolanib will continue at the same dose level post Radiation Therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Estimate the maximum tolerated dose (MTD) of crenolanib in pediatric research participants with newly diagnosed DIPGTime frame: 2.5 years
  2. Estimate the MTD of crenolanib in children and young adults with recurrent/refractory HGG including DIPGTime frame: 2.5years
  3. Characterize the pharmacokinetics of crenolanib in pediatric patients and relate drug disposition to toxicityTime frame: 2.5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • St. Jude Children's Research Hospital

    Memphis, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.